Skip to main content
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update
- Positive SER-109 Type B FDA meeting - - Company to initiate new Phase 2 SER-109 clinical trial that, as agreed to by the FDA, may qualify as a Pivotal Study with achievement of a persuasive clinical effect and addressing FDA requirements - - Continued pipeline progress with both SER-287 and SER-262 Phase 1b studies; Both data read-outs expected in the second half of 2017 - - Conference call at 8 a.m. ET today - CAMBRI... 
Seres Therapeutics to Initiate New SER-109 Clinical Study
– Positive SER-109 Type B FDA meeting – – Seres and FDA reach agreement on key design elements of a new SER-109 Phase 2 study in patients with multiply recurrent C. difficile infection – – New trial may qualify as a Pivotal Study with achievement of a persuasive clinical effect and addressing FDA requirements – – Conference call at 8 a.m. ET today – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 16, 2017-- Seres Therape... 
Seres Therapeutics to Host Fourth Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on March 16, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2017-- Seres Therapeutics, Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, March 16, 2017 at 8:00 a.m. ET to discuss fourth quarter 2016 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (internatio... 
There are currently no upcoming events scheduled.
Stock Quote
 + 0.42 (4.30%)
04/25/17 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

Data provided by Nasdaq. Minimum 15 minutes delayed.